BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gado F, Meini S, Bertini S, Digiacomo M, Macchia M, Manera C. Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: implications for drug discovery. Future Med Chem 2019;11:2019-37. [PMID: 31517528 DOI: 10.4155/fmc-2019-0005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Ferrisi R, Ceni C, Bertini S, Macchia M, Manera C, Gado F. Medicinal Chemistry approach, pharmacology and neuroprotective benefits of CB2R modulators in neurodegenerative diseases. Pharmacol Res 2021;170:105607. [PMID: 34089867 DOI: 10.1016/j.phrs.2021.105607] [Reference Citation Analysis]
2 Aderibigbe AO, Pandey P, Doerksen RJ. Negative allosteric modulators of cannabinoid receptor 1: Ternary complexes including CB1, orthosteric CP55940 and allosteric ORG27569. J Biomol Struct Dyn 2021;:1-19. [PMID: 33480332 DOI: 10.1080/07391102.2021.1873187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gado F, Mohamed KA, Meini S, Ferrisi R, Bertini S, Digiacomo M, D'Andrea F, Stevenson LA, Laprairie RB, Pertwee RG, Manera C. Variously substituted 2-oxopyridine derivatives: Extending the structure-activity relationships for allosteric modulation of the cannabinoid CB2 receptor. Eur J Med Chem 2021;211:113116. [PMID: 33360803 DOI: 10.1016/j.ejmech.2020.113116] [Reference Citation Analysis]
4 Whiting ZM, Yin J, de la Harpe SM, Vernall AJ, Grimsey NL. Developing the Cannabinoid Receptor 2 (CB2) pharmacopoeia: past, present, and future. Trends Pharmacol Sci 2022:S0165-6147(22)00137-7. [PMID: 35906103 DOI: 10.1016/j.tips.2022.06.010] [Reference Citation Analysis]
5 Saldaña-Shumaker SL, Grenning AJ, Cunningham CW. Modern approaches to the development of synthetic cannabinoid receptor probes. Pharmacol Biochem Behav 2021;203:173119. [PMID: 33508249 DOI: 10.1016/j.pbb.2021.173119] [Reference Citation Analysis]
6 Meini S, Gado F, Stevenson LA, Digiacomo M, Saba A, Codini S, Macchia M, Pertwee RG, Bertini S, Manera C. PSNCBAM-1 analogs: Structural evolutions and allosteric properties at cannabinoid CB1 receptor. Eur J Med Chem 2020;203:112606. [PMID: 32682199 DOI: 10.1016/j.ejmech.2020.112606] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 An D, Peigneur S, Hendrickx LA, Tytgat J. Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products. Int J Mol Sci 2020;21:E5064. [PMID: 32709050 DOI: 10.3390/ijms21145064] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
8 Nguyen T, Gamage TF, Decker AM, Finlay DB, Langston TL, Barrus D, Glass M, Harris DL, Zhang Y. Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids. Bioorg Med Chem 2021;41:116215. [PMID: 34015703 DOI: 10.1016/j.bmc.2021.116215] [Reference Citation Analysis]
9 Stasiulewicz A, Znajdek K, Grudzień M, Pawiński T, Sulkowska AJI. A Guide to Targeting the Endocannabinoid System in Drug Design. Int J Mol Sci 2020;21:E2778. [PMID: 32316328 DOI: 10.3390/ijms21082778] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
10 Seillier A. The endocannabinoid system as a therapeutic target for schizophrenia: Failures and potentials. Neurosci Lett 2021;759:136064. [PMID: 34146641 DOI: 10.1016/j.neulet.2021.136064] [Reference Citation Analysis]
11 Greco R, Demartini C, Zanaboni AM, Francavilla M, De Icco R, Ahmad L, Tassorelli C. The endocannabinoid system and related lipids as potential targets for the treatment of migraine-related pain. Headache 2022;62:227-40. [PMID: 35179780 DOI: 10.1111/head.14267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Polini B, Cervetto C, Carpi S, Pelassa S, Gado F, Ferrisi R, Bertini S, Nieri P, Marcoli M, Manera C. Positive Allosteric Modulation of CB1 and CB2 Cannabinoid Receptors Enhances the Neuroprotective Activity of a Dual CB1R/CB2R Orthosteric Agonist. Life (Basel) 2020;10:E333. [PMID: 33302569 DOI: 10.3390/life10120333] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Lin X, Xu Z, Carey L, Romero J, Makriyannis A, Hillard CJ, Ruggiero E, Dockum M, Houk G, Mackie K, Albrecht PJ, Rice FL, Hohmann AG. A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse. Pain 2021. [PMID: 35001054 DOI: 10.1097/j.pain.0000000000002502] [Reference Citation Analysis]
14 Gado F, Ferrisi R, Polini B, Mohamed KA, Ricardi C, Lucarini E, Carpi S, Domenichini F, Stevenson LA, Rapposelli S, Saccomanni G, Nieri P, Ortore G, Pertwee RG, Ghelardini C, Di Cesare Mannelli L, Chiellini G, Laprairie RB, Manera C. Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands. J Med Chem 2022. [PMID: 35849804 DOI: 10.1021/acs.jmedchem.2c00582] [Reference Citation Analysis]
15 Piscitelli F, Di Marzo V. Cannabinoids: a class of unique natural products with unique pharmacology. Rend Fis Acc Lincei 2021;32:5-15. [DOI: 10.1007/s12210-020-00966-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Jakowiecki J, Abel R, Orzeł U, Pasznik P, Preissner R, Filipek S. Allosteric Modulation of the CB1 Cannabinoid Receptor by Cannabidiol-A Molecular Modeling Study of the N-Terminal Domain and the Allosteric-Orthosteric Coupling. Molecules 2021;26:2456. [PMID: 33922473 DOI: 10.3390/molecules26092456] [Reference Citation Analysis]